The impact of coronary revascularization on vessel-specific coronary flow capacity and long-term outcomes: a serial $[^{15}\text{O}]\text{H}_2\text{O}$ positron emission tomography perfusion imaging study

Ruben W. de Winter, Ruurt A. Jukema, Pepijn A. van Diemen, Stefan P. Schumacher, Roel S. Driessen, Wynand J. Stuijfzand, Henk Everaars, Michiel J. Bom, Albert C. van Rossum, Peter M. van de Ven, Niels J. Verouden, Alexander Nap, Pieter G. Rajmakers, Ibrahim Danad, and Paul Knaapen

1Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; 2Department of Epidemiology & Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; and 3Department of Radiology, Nuclear Medicine & PET Research, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Received 16 July 2021; editorial decision 17 November 2021; accepted 25 November 2021

Aims

Coronary flow capacity (CFC) integrates quantitative hyperaemic myocardial blood flow (hMBF) and coronary flow reserve (CFR) to comprehensively assess physiological severity of coronary artery disease (CAD). This study evaluated the effects of revascularization on CFC as assessed by serial $[^{15}\text{O}]\text{H}_2\text{O}$ positron emission tomography (PET) perfusion imaging.

Methods and results

A total of 314 patients with stable CAD underwent $[^{15}\text{O}]\text{H}_2\text{O}$ PET imaging at baseline and after myocardial revascularization to assess changes in hMBF, CFR, and CFC in 415 revascularized vessels. Using thresholds for ischaemia and normal perfusion, vessels were stratified in five CFC categories: myocardial steal, severely reduced CFC, moderately reduced CFC, minimally reduced CFC, and normal flow. Additionally, the association between CFC increase and the composite endpoint of death and non-fatal myocardial infarction (MI) was studied. Vessel-specific CFC improved after revascularization ($P < 0.01$). Furthermore, baseline CFC was an independent predictor of CFC increase ($P < 0.01$). The largest changes in $\Delta$hMBF ($0.90 \pm 0.74, 0.93 \pm 0.65, 0.79 \pm 0.74, 0.48 \pm 0.61,$ and $0.29 \pm 0.66 \text{ mL/min/g}$) and $\Delta$CFR ($1.01 \pm 0.88, 0.99 \pm 0.69, 0.87 \pm 0.88, 0.66 \pm 0.91,$ and $-0.01 \pm 1.06$) were observed in vessels with lower baseline CFC ($P < 0.01$ for both). During a median follow-up of 3.5 (95% CI 3.1–3.9) years, an increase in CFC was independently associated with lower rates of death and non-fatal MI (HR 0.43, 95% CI 0.19–0.98, $P = 0.04$).

Conclusion

Successful revascularization results in an increase in CFC. Furthermore, baseline CFC was an independent predictor of change in hMBF, CFR, and subsequently CFC. In addition, an increase in CFC was associated with a favourable outcome in terms of death and non-fatal MI.
Graphical Abstract

This study comprised 314 patients with stable CAD and evaluated the effects of revascularization on CFC as assessed by serial $[^{15}O]H_2O$ PET perfusion imaging. Revascularization resulted in a significant increase in CFC. Furthermore, baseline CFC was an independent predictor of change in hMBF, CFR, and subsequently CFC. $[^{15}O]H_2O$ PET-derived CFC holds the potential to identify vessels in which absolute myocardial perfusion will improve with revascularization. Our study broadens the CFC concept to $[^{15}O]H_2O$ PET perfusion imaging and therewith expands standardization of absolute flow data interpretation. CAD, coronary artery disease; CFC, coronary flow capacity; CFR, coronary flow reserve; hMBF, hyperaemic myocardial blood flow; PET, positron emission tomography.

Keywords
$[^{15}O]H_2O$ positron emission tomography • quantitative myocardial perfusion • coronary flow capacity • coronary revascularization
Introduction

Observational studies have shown that the clinical benefit of coronary revascularization in patients with stable coronary artery disease (CAD) is dependent on the severity of myocardial perfusion impairment and the extent of ischaemia reduction.1-3 However, randomized trials did not demonstrate a favourable prognostic effect with initial ischaemia-driven revascularization compared to optimal medical therapy. Hence the effect of revascularization in unselected patients with stable CAD remains controversial.4,5 Therefore, more accurate diagnostic tools are needed to identify patients in whom revascularization will restore myocardial perfusion and potentially improve prognosis. The concept of coronary flow capacity (CFC), developed by Johnson and Gould6 using 82Rb positron emission tomography (PET) imaging, combines hyperaemic myocardial blood flow (hMBF) and coronary flow reserve (CFR) with thresholds for definite or possible ischaemia to comprehensively assess all relevant coronary flow characteristics. An advantage of CFC is its applicability to all modalities that measure coronary flow, which might enable standardization for physiological integration of quantitative myocardial perfusion indices. Invasively and non-invasively derived CFC have been shown to improve identification of lesions that benefit from revascularization therapy in terms of coronary flow increase, thus guiding patient selection in whom revascularization may result in improved clinical outcomes.7-10 To date, [15O]H2O PET imaging studies evaluating the impact of revascularization on CFC in relation to traditional perfusion metrics and long-term outcomes are lacking. This study sought to evaluate the effects of revascularization on regional changes in CFC and the prognostic effect of CFC increase in patients undergoing serial [15O]H2O PET perfusion imaging.

Methods

Study population

The study comprised 314 prospectively included patients with stable CAD who underwent [15O]H2O PET perfusion imaging at baseline and after clinically driven percutaneous or surgical coronary revascularization between 2012 and 2019. The clinical indication for revascularization was based on angina, evaluation of ischaemia, viability testing when available, and invasive coronary angiography with additional interrogation of coronary lesions by fractional flow reserve (FFR) according to contemporary guidelines.11 Vessel-specific CFC classification was performed after the indication for revascularization was established. As such, baseline CFC was not used to interpret myocardial perfusion values in order to decide for downstream referral to invasive coronary angiography and subsequent coronary revascularization after initial stress imaging. In the study cohort, 96 patients (31%) were included in an imaging study protocol and were scheduled to undergo invasive coronary angiography and revascularization, irrespective of PET results. The revascularization strategy was left at the discretion of the operator. Only successfully revascularized vessels were included in the analyses. The study was approved by the institutional Medical Ethics Committee and complied with the Declarations of Helsinki. All participants provided written informed consent.

[15O]H2O PET acquisition

[15O]H2O PET perfusion scans were acquired using a hybrid PET/computed tomography (CT) device (Gemini TF 64 (15% of patients) and Ingenuity TF 128, Philips Healthcare, Best, The Netherlands). The scanning protocol has been described in detail previously.12 Briefly, patients underwent a 6-min dynamic scan protocol commencing simultaneously with an injection of 370 MBq [15O]H2O during resting and adenosine (140 µg/kg/min) induced hyperaemic conditions. Perfusion indices were calculated from parametric MBF images which were used for semiautomated heart segment definition according to the standard 17-segment model of the American heart Association (Supplementary data online, Figure S1).13 Quantitative analysis for each of the three coronary territories (LAD, Cx, and RCA) was performed to obtain resting MBF and hMBF in mL/min/g of perfusable tissue, using in-house developed software (Cardiac VUer).14 CFR was defined as the ratio between hyperaemic and resting MBF. PET perfusion indices of the three vascular regions were used to calculate vessel-specific CFC before and after revascularization.

[15O]H2O PET thresholds for coronary flow capacity

Vessels were stratified into five CFC categories (myocardial steal, severely reduced CFC, moderately reduced CFC, minimally reduced CFC, and normal flow) and plotted in a 2D graph as proposed by Johnson and Gould.6 Myocardial steal is defined as myocardium with a CFR below unity, denoting that hMBF is lower than resting MBF.6 Danad et al.12 reported thresholds associated with myocardial ischaemia as assessed by [15O]H2O PET and described optimal cut-off values of 2.3 mL/min/g and 2.5 for hMBF and CFR, respectively. Vessels within the ischaemic range with hMBF <1.5 mL/min/g and CFR <2.5 were defined as severely reduced CFC. Vessels with hMBF <2.3 mL/min/g and CFR <2.5, yet with either hMBF >1.5 mL/min/g or CFR >1.5 were classified as moderately reduced CFC. To define perfusion thresholds for [15O]H2O in patients with normal flow, we calculated the average hMBF and CFR in 155 patients from a study cohort previously described by Driessen et al.,15 in whom obstructive CAD was ruled out (coronary artery calcium score 0 and CT coronary angiography showing no obstructive lesions). In these patients, mean hMBF was 3.66±1.30 mL/min/g and mean CFR 3.69±1.48. Vessels with hMBF and CFR >0.5 standard deviation (SD) below these normal values, yet with either hMBF or CFR above the ischaemic thresholds, were stratified to the minimally reduced CFC category. Revascularized vessels with either hMBF >3.01 mL/min/g or CFR >2.95 were defined as vessels with normal flow. Two case examples are illustrated in Supplementary data online, Figure S2.

Clinical follow-up

Observers blinded to PET perfusion results collected clinical follow-up using national registry databases, electronic medical patient records and standardized telephonic assessment. The occurrence of death and non-fatal myocardial infarction (MI) during follow-up was assessed and events were adjudicated according to the definitions used in current guidelines.11 Registration of events started from the moment of successful follow-up PET perfusion imaging. We used a hierarchical end-point definition with death being considered more severe than non-fatal MI.

Statistical analysis

Categorical variables are summarized by frequencies and percentages, whereas continuous variables are displayed as mean ± SD and median (interquartile range) as appropriate. The Wilcoxon signed-rank test was used to assess changes in CFC before and after revascularization at a per-vessel level. Generalized estimating equations analysis was used to compare the proportion of vessels in which CFC increased after revascularization between baseline CFC categories, adjusting for potential confounders and accounting for correlation of regional perfusion outcomes within different revascularized territories within the same patient.
Furthermore, linear mixed model analyses were used to test whether mean changes in regional hMBF and CFR during follow-up differed between the 5 baseline CFC groups. The linear mixed models accounted for within-patient correlation of PET perfusion results by including a random effect for patient in the model. We compared mean changes in hMBF and CFR between baseline CFC groups using a Bonferroni post hoc correction to account for multiple testing. Additionally, a linear mixed model was fitted to assess the mean change in hMBF and CFR between vessels with concordant low perfusion values below the ischaemic cut-offs and vessels with either hMBF or CFR above the ischaemic threshold. A similar analysis was used to assess the independent predictive value of baseline CFC and quantitative stress perfusion on the absolute increase in hMBF following revascularization. The coefficient of variation (SD/mean × 100%) was calculated to evaluate test–retest repeatability. Kaplan–Meier curves with log-rank testing were used to compare event-free survival between patients whose CFC increased and the remaining patients. Those who underwent revascularization of multiple vessels were stratified in the CFC increase group if CFC augmentation of all revascularized vessels was observed. Normal flow capacity cannot increase in CFC category, thus patients with only normal flow were excluded from the survival analyses. Median follow-up time was calculated using the reverse Kaplan–Meier estimator. A multivariable Cox regression analysis was performed to determine whether CFC increase was associated with event-free survival after adjustment for clinical characteristics and CAD risk factors. A P-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 26.0 (IBM SPSS Statistics, Armonk, NY, USA).

Results

Study population
A total of 314 patients (63 ± 10 years, 86% male) underwent [15O]H2O PET perfusion imaging before and after revascularization (Table 1). In 80 patients (25%), more than one vessel was revascularized, resulting in a total 415 vessels. Of these, 369 (89%) and 46 (11%) were revascularized by percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), respectively. The median interval between baseline PET imaging and revascularization was 27 (10–52) days, followed by a median interval of 96 (50–113) days until follow-up PET imaging. During this 96-day interval, no cardiac events occurred.

The impact of revascularization on regional CFC
At baseline, 4 (1%), 76 (18%), 211 (51%), 69 (17%), and 55 (13%) vessels were classified as myocardial steal, severely reduced CFC, moderately reduced CFC, minimally reduced CFC, and normal flow, respectively. In the normal flow group, 7 (2%) vessels had both hMBF and CFR above the normal CFC thresholds. After revascularization, vessel-specific CFC was classified as myocardial steal in 3 (1%), severely reduced in 13 (3%), moderately reduced in 119 (29%), minimally reduced in 100 (24%), and normal in 180 (43%) of 415 vessels. An overall increase in CFC was observed (P < 0.01) (Figure 1). After revascularization, 243 (59%) vessels increased in CFC group, whereas in 144 (35%) vessels CFC did not change and 28 (7%) vessels decreased in CFC group. Figure 1 illustrates the impact of revascularization on vessel-specific CFC according to the five baseline CFC categories. The distribution of vessels at baseline and after revascularization according to absolute hMBF and CFR is depicted in Figure 2. Baseline CFC independently predicted regional CFC improvement (Table 2). The integration of absolute values of hMBF and CFR in a 2D plane before and after revascularization may represent a quantification of CFC improvement (Supplementary data online, Figure S5).

Baseline CFC and regional changes in absolute myocardial perfusion
Changes in absolute myocardial perfusion after revascularization were stratified according to baseline CFC groups (Table 3). The increase of hMBF was higher with lower baseline CFC groups (P < 0.01). Post hoc tests revealed that mean hMBF improvement was higher in the severely reduced CFC group compared to the
moderately reduced ($P = 0.01$), minimally reduced ($P < 0.01$), and normal flow groups ($P < 0.01$). Furthermore, higher hMBF increases were observed for moderately reduced CFC compared to minimally reduced CFC and normal flow ($P < 0.01$ for both), and for minimally reduced CFC compared to normal flow ($P = 0.04$). Similarly, CFR changes differed between baseline CFC groups ($P < 0.01$). Post hoc tests showed greater CFR increase in vessels with severely reduced baseline CFC compared to vessels with minimally reduced CFC ($P = 0.04$) and normal flow ($P < 0.01$). Furthermore, CFR increase was higher in vessels with minimally reduced CFC compared to normal flow ($P < 0.01$). Higher baseline CFC group was independently associated with diminished increase in hMBF and CFR ($P < 0.01$ for both) (Supplementary data online, Table S1). Additionally, the increase in hMBF and CFR following revascularization was higher in vessels with concordant perfusion values below the ischaemic cut-offs, compared to vessels with either hMBF or CFR above the ischaemic threshold ($P < 0.01$ for both hMBF and CFR) (Supplementary data online, Figure S4). In a combined model with baseline CFC and quantitative hMBF, baseline CFC remained an independent predictor of absolute stress perfusion increase (Supplementary data online, Table S2). The test–retest variability for non-revascularized vessels is depicted in Supplementary data online, Table S3.

**Prognostic value of CFC improvement**
Outcome analyses were performed in 271 patients. During a median follow-up of 3.5 (95% CI 3.1–3.9) years, 26 (10%) patients experienced death or non-fatal MI, with 19 deaths (7%) and 7 non-fatal MIs (3%). Kaplan–Meier estimates, stratified by the occurrence of CFC increase are depicted in Figure 3. Patients in whom CFC improved had superior event-free survival ($P = 0.04$). CFC increase remained

---

**Figure 1** Vessel-specific CFC before and after revascularization. Vessel-specific changes in CFC category between baseline and follow-up are demonstrated for 415 revascularized vessels. An overall improvement in CFC can be observed. Additionally, for all five baseline CFC groups, the bar graphs indicate the vessel distribution after revascularization, showing more frequent CFC increase in vessels with lower baseline CFC. CFC, coronary flow capacity.
independently associated with superior outcome after adjusting for clinical characteristics and CAD risk factors (HR 0.43, 95% CI 0.19–0.98, P = 0.04) (Supplementary data online, Table S4).

Discussion

CFC is an integration of hMBF and CFR providing a comprehensive assessment across the entire spectrum of myocardial ischaemia spanning from epicardial obstructive stenosis to microvascular CAD. To the best of our knowledge, our study is the first to report the concept of CFC using [15O]H2O PET perfusion imaging. Germane to this, serial [15O]H2O PET scans were performed to assess the impact of revascularization therapy on CFC. An overall increase in vessel-specific CFC was observed in patients who underwent percutaneous or surgical revascularization. Furthermore, baseline CFC was an independent predictor of change in hMBF, CFR, and subsequently CFC. In addition, an increase in flow capacity was independently associated with a favourable outcome resulting in a lower incidence of death and non-fatal MI.

The CFC concept, defining [15O]H2O PET-specific CFC thresholds

Vasodilator capacity is closely related to demand ischaemia and is a measure of microcirculatory autoregulation reserve. CFC was proposed to assess the mismatch between myocardial oxygen demand and the coronary vasodilator reserve by combining CFR and absolute stress perfusion, providing a physiological framework for quantitative classification of CAD severity. Vessel-specific perfusion thresholds for classification of myocardial territories into CFC categories have been validated for 82Rb PET and invasive coronary flow measurements. Quantitative [15O]H2O PET thresholds for hMBF and CFR for assessment of significant CAD have been validated by relating perfusion values to invasive coronary angiography in conjunction with FFR as a reference. We used these cut-offs to identify vessels with reduced CFC within the ischaemic range. The original CFC concept yields classification of severely reduced and moderately reduced ischaemia-related CFC categories. Similarly, we aimed to further categorize differences in severe and moderate perfusion defects within the ischaemic range, since myocardial perfusion improvement after revascularization may differ within these subgroups. To distinguish between severely and moderately reduced CFC, we used perfusion values <1.5 mL/min/g for hMBF and <1.5 for CFR in accordance with a Joint position paper by the Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology. Johnson and Gould established thresholds for a minimally reduced CFC category, a subgroup in which patients did not have clinically pertinent ischaemia yet with perfusion values that did not fit in the normal flow range, by subtracting 1 SD from the average perfusion indices in young, healthy volunteers. The division of CFC categories in minimally reduced CFC and normal flow may allow for additional evaluation of coronary vasodilator capacity in non-

![Figure 2](https://academic.oup.com/ehjci/advance-article/doi/10.1093/ehjci/jeab263/6456170)
Table 2  Predictors of CFC improvement

| CFC increase                                                                 | OR (95% CI)                  | P-value |
|------------------------------------------------------------------------------|-----------------------------|---------|
| Baseline CFC groups                                                         |                             |         |
| Severely reduced CFC vs. moderately reduced CFC                             | 4.84 (2.12–11.09)           | <0.01   |
| Severely reduced CFC vs. minimally reduced CFC                              | 5.77 (2.20–15.16)           |         |
| Moderately reduced CFC vs. minimally reduced CFC                            | 1.19 (0.67–2.13)            |         |
| Demographics                                                                |                             |         |
| Gender (male vs. female)                                                     | 0.43 (0.17–1.10)            | 0.08    |
| Age (years)                                                                 | 0.99 (0.96–1.02)            | 0.37    |
| BMI                                                                          | 1.00 (0.94–1.07)            | 0.99    |
| Cardiovascular risk factors                                                  |                             |         |
| Hypertension                                                                | 1.37 (0.75–2.48)            | 0.30    |
| Hypercholesterolaemia                                                        | 1.18 (0.61–1.84)            | 0.83    |
| Diabetes mellitus                                                            | 0.69 (0.38–1.25)            | 0.22    |
| Family history of CAD                                                        | 0.96 (0.52–1.64)            | 0.87    |
| Smoking                                                                      | 1.55 (0.79–3.08)            | 0.21    |
| Cardiac history                                                              |                             |         |
| History of MI                                                                | 0.56 (0.31–1.00)            | 0.05    |
| History of PCI                                                               | 0.98 (0.51–1.89)            | 0.95    |
| History of CABG                                                              | 0.48 (0.21–1.08)            | 0.07    |
| Medication                                                                   |                             |         |
| Aspirin                                                                      | 1.07 (0.34–3.33)            | 0.91    |
| β-Blocker                                                                    | 1.11 (0.54–2.26)            | 0.78    |
| ACE inhibitor/ARB                                                            | 0.72 (0.40–1.3)             | 0.28    |
| Statin                                                                       | 0.76 (0.31–1.85)            | 0.54    |
| Calcium channel blocker                                                      | 0.95 (0.52–1.75)            | 0.87    |
| Revascularization                                                            |                             |         |
| Surgical revascularization                                                   | 0.86 (0.33–2.29)            | 0.77    |

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CFC, coronary flow capacity; LAD, left anterior descending coronary artery; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.

Table 3  Comparison of change in [15O]H2O PET perfusion between baseline CFC groups

| Time point | Baseline | Follow-up | Δ perfusion | Overall P-value |
|------------|----------|-----------|-------------|-----------------|
| Hyperaemic MBF (mL/min/g)          |          |           |             |                 |
| Baseline CFC group                 |          |           |             |                 |
| Steal (n = 4)                       | 0.88 ± 0.26 | 1.78 ± 0.89 | 0.90 ± 0.74 | <0.01           |
| Severely reduced CFC (n = 76)       | 1.12 ± 0.21 | 2.05 ± 0.72 | 0.93 ± 0.65 |                 |
| Moderately reduced CFC (n = 211)    | 1.62 ± 0.34 | 2.41 ± 0.82 | 0.79 ± 0.74 |                 |
| Minimally reduced CFC (n = 69)      | 2.21 ± 0.37 | 2.70 ± 0.62 | 0.48 ± 0.61 |                 |
| Normal flow (n = 55)                | 2.53 ± 0.62 | 2.82 ± 0.83 | 0.29 ± 0.66 |                 |
| CFR                               |          |           |             |                 |
| Steal                               | 0.89 ± 0.07 | 1.91 ± 0.94 | 1.01 ± 0.88 | <0.01           |
| Severely reduced CFC                | 1.29 ± 0.13 | 2.28 ± 0.69 | 0.99 ± 0.69 |                 |
| Moderately reduced CFC              | 1.91 ± 0.30 | 2.78 ± 0.86 | 0.87 ± 0.88 |                 |
| Minimally reduced CFC               | 2.52 ± 0.32 | 3.18 ± 1.01 | 0.66 ± 0.91 |                 |
| Normal flow                         | 3.43 ± 0.49 | 3.43 ± 0.95 | -0.001 ± 1.06|                 |

Values are presented as mean ± SD.
CFC, coronary flow capacity; CFR, coronary flow reserve; Δ, delta; MBF, myocardial blood flow; PET, positron emission tomography.
ischaemic regions with reduced perfusion compared to vessels without atherosclerotic disease. In this study, the threshold for minimally reduced CFC was calculated 0.5 SD below the average of hMBF and CFR in patients in whom significant CAD was excluded. Contrary to healthy individuals, our cohort might best represent patients without pathological impairment of coronary vasodilator capacity as encountered in daily clinical practice. The SD of our normal control group did not allow for a similar method as used by Johnson and Gould without deviating from the original CFC concept as it selects patients too close to the predefined ischaemic thresholds for $^{[15]O}$H$_2$O PET. An apparent characteristic of 15O-water is the wide range of MBF values it provides in both healthy volunteers and patients with cardiovascular risk factors without obstructive CAD. As such, an SD value of 1 seems not to be feasible for $^{[15]O}$H$_2$O PET.

The effect of revascularization on myocardial perfusion

An overall increase in vessel-specific CFC was observed. Interestingly, the increase was more pronounced in vessels with lower CFC at baseline, independent of clinical CAD risk factors. Similarly, in the COURAGE nuclear substudy, a reduction in inducible ischaemia was observed with PCI added to optimal medical therapy, with greater benefit in those patients with the largest ischaemic burden at baseline. A previous study by Bober et al. using 82Rb PET illustrated the value of CFC for prediction of regional improvement in hMBF, with a more pronounced restoration of perfusion in regions with reduced CFC at baseline. In addition, invasively derived CFC was shown to better detect lesions in which a restoration of coronary flow was expected in comparison to FFR, instantaneous wave-free ratio and CFR. Our study confirms and extends previous observations that CFC may guide identification of lesions with the best potential for improved vessel-related outcomes after revascularization.

Clinical outcomes after revascularization

Restoration of vasodilator capacity in patients with significant ischaemic burden at baseline may identify patients that benefit most from revascularization. In contrast, revascularization without a corresponding increase in coronary blood flow may be associated with detrimental patient outcome. Indeed, several studies showed that improvement of FFR after revascularization is a strong independent predictor of adverse cardiovascular events. Additionally, Driessen et al. reported a close agreement between absolute changes in intra-coronary pressure following PCI and improvement of $^{[15]O}$H$_2$O PET stress perfusion. This finding underscores that the prognostic benefit of restored post-PCI pressure may be mediated by normalization of myocardial perfusion. Recently, the ISCHEMIA trial, which randomized more than 5000 patients with stable CAD and predefined substantial ischaemic burden, did not find evidence of superior patient outcome with an initial invasive strategy. ISCHEMIA showed an improvement of symptoms and quality of life in the revascularization group but did not quantify ischaemia reduction. Only patients with a history of heart failure and reduced left ventricular function benefited from an invasive approach, illustrating the need to identify patients with stable CAD most likely to benefit from coronary revascularization. In this context, the cross-modality CFC concept seems promising. Using flow wires, van de Hoef et al. found that reduced baseline CFC was associated with higher major adverse cardiovascular event rates compared to normal flow. In a study of 3774 routine diagnostic rest-stress 82Rb PET scans, regional CFC before intervention was directly associated with the risk of death and non-fatal MI and a >50% risk reduction was observed after revascularization in lesions with severe CFC perfusion abnormalities. Furthermore, regional severely reduced baseline CFC was associated with the highest risk of all-cause mortality, which was attenuated by restoration of myocardial perfusion. Importantly, these studies used baseline CFC as a predictor for patient outcome, whereas this study extend to their findings by assessing the increase in flow capacity after revascularization in relation to prognosis. We found that an increase in vessel-specific CFC was associated with lower rates of death and non-fatal MI, independent of CAD risk factors. Notably, patients with normal flow at baseline were excluded from the survival analyses. Thus, the increased risk of unfavourable outcome relates to patients that did not benefit from revascularization in terms of CFC increase, despite a reduced CFC at baseline. The potential of CFC for integrated risk stratification in patients evaluated for ischaemic heart disease to select patients with anticipated benefit from revascularization is illustrated in this study with $^{[15]O}$H$_2$O PET.

Limitations

First, this is an observational single-centre study. Secondly, coronary microvascular function was not assessed and vessels in which revascularization was not performed were not included, hence the quantitative impact of diffuse CAD on $^{[15]O}$H$_2$O-derived flow capacity was not evaluated. Thirdly, Johnson and Gould applied a regional, per-pixel (1344 pixels) combination to calculate flow capacity maps accounting for individual patient variation in coronary artery distribution. Our study lacks this granular CFC size-severity classification and may average absolute perfusion towards higher values compared to a more advanced segmental model, possibly diluting the observed effect of revascularization on $^{[15]O}$H$_2$O PET-derived CFC. These
methodological differences likely contributed to the observed differences between our ischaemia threshold values and those of Johnson and Gould used to define CFC categories within the ischaemic range. Furthermore, Johnson and Gould evaluated electrocardiograms, perfusion defects and angina symptoms during stress testing to rigorously define clinical CFC thresholds for severely and moderately reduced flow.6,9 In our study, such robust clinical data were not available. In the absence of documented cut-offs to define CFC categories for $^{15}$O$\text{H}_2$O PET, we established CFC thresholds that need to be validated in an external, larger patient cohort. Of note, differences in perfusion thresholds for severely and moderately reduced CFC between this study and previous work by Johnson and Gould may be related to the different definitions used to relate quantitative PET indices to myocardial ischaemia and severe CFC reduction. Finally, the limited event rate in this study hampered complex survival analyses and outcome data stratified to $^{15}$O$\text{H}_2$O PET-derived CFC values require validation in larger studies.

Conclusion
CFC combines absolute stress flow, flow reserve and ischaemic thresholds into a physiological measure for quantitative classification of CAD severity. Revascularization resulted in a significant increase in CFC. Furthermore, baseline CFC was an independent predictor of change in hMBF, CFR, and subsequently CFC. CFC measured with serial $^{15}$O$\text{H}_2$O PET perfusion imaging holds the potential to identify vessels in which absolute myocardial perfusion will improve with revascularization. Finally, improvement of flow capacity following revascularization may affect clinical outcomes. These findings extend the potential application of CFC to $^{15}$O$\text{H}_2$O PET perfusion imaging and expand standardization of absolute flow data interpretation.

Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular Imaging online.

Conflict of interest: None declared.

Funding
None declared.

Data availability
Data supporting the findings of this study are available upon reasonable request to the corresponding author (Paul Knaapen).

References
1. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900–7.
2. Johnson NP, Tóth GG, Lai D, Zhu H, Açar G, Agostani P et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol 2014;64:1641–54.
3. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283–91.
4. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–16.
5. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE et al. ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2015;372:1395–407.
6. Johnson NP, Gould KL. Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiological severity. JACC Cardiovasc Imaging 2013;6:500–9.
7. Bobe RJ, Milan R, Oktay AA, Javed F, Polin NM, Maron DP. PET imaging on myocardial blood flow as assessed by positron emission tomography. Eur J Nucl Med Mol Imaging 2019;46:1226–39.
8. Murai T, Steghuis VE, van de Hoef TP, Wijndtens GWMM, Hoshino M, Kanay Y et al. Coronary flow capacity to identify stenosis associated with coronary flow improvement after revascularization: a combined analysis from DEFINE FLOW and IDEAL. Am Heart J 2017;182:1105–13.
9. Gould KL, Johnson NP, Roby AE, Nguyen T, Kirkeeide R, Haynie M et al. Regional, artery-specific thresholds of quantitative myocardial perfusion by PET associated with reduced myocardial infarction and death after revascularization in stable coronary artery disease. J Nucl Med 2019;60:410–7.
10. Gould KL, Kitkungvan D, Johnson NP, Nguyen T, Kirkeeide R, Bui L et al. Mortality prediction by quantitative pet perfusion expressed as coronary flow capacity with and without revascularization. JACC Cardiovasc Imaging 2021;14:1020–34.
11. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al.; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:86–165.
12. Danad I, Uusitalo V, Kero T, Saraste A, Rajmakkers PG, Lammertsma AA et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative $^{15}$O$\text{H}_2$O PET imaging. J Am Coll Cardiol 2014;64:1464–73.
13. Correa MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WJ et al.; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:393–42.
14. Harms HJ, Knaapen P, de Haan S, Hubmers J, Lammertsma AA, Lubberink M et al.; Automatic generation of absolute myocardial blood flow images using $^{15}$O$\text{H}_2$O and a clinical PET/CT scanner. Eur J Nucl Med Mol Imaging 2011;38:930–9.
15. Driessen RS, Bon MJ, van Diemen PA, Schumacher SP, Leonora RM, Everaars H et al. Incremental prognostic value of hybrid $^{15}$O$\text{H}_2$O positron emission tomography-computed tomography: combining myocardial blood flow, coronary stenosis severity, and high-risk plaque morphology. Eur Heart J Cardiovasc Imaging 2020;21:105–13.
16. van de Hoef TP, Echavarria-Pinto M, van Lavieren MA, Meuwissen M, Sennys PW, Tijssen JG et al. Diagnostic and prognostic implications of coronary flow capacity: a comprehensive cross-modality physiological concept in ischemic heart disease. JACC Cardiovasc Imaging 2015;8:1670–80.
17. Murphy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P et al.; ASNC Board of Directors. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI PET/CT Council and the ASNC. J Nucl Med 2018;59:273–93.
18. Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res 2001;50:151–61.
19. Danad I, Rajmakkers PG, Appelman YE, Harms HJ, de Haan S, van den Oever ML et al. Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative $^{15}$O$\text{H}_2$O PET/CT study. Eur J Nucl Med Mol Imaging 2012;39:102–12.
20. Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J 2015;36:3182–8.
21. Pijs NH, Klauß V, Siebert U, Powers E, Takazawa K, Fearon WF et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation 2002;105:2950–4.
22. Piroth Z, Toth GG, Tonino PAL, Barbato E, Aghimandi S, Curzen N et al. Prognostic value of fractional flow reserve measured immediately after drug-eluting stent implantation. Circ Cardiovasc Interv 2017;10:e005233.

23. Driessen RS, Danad I, Stuijfzand WJ, Schumacher SP, Knuti J, Mäki M et al. Impact of revascularization on absolute myocardial blood flow as assessed by serial [(15)O]H(2)O positron emission tomography imaging: a comparison with fractional flow reserve. Circ Cardiovasc Imaging 2018;11:e007417.

24. Spertus JA, Jones PG, Maron DJ, O’Brien SM, Reynolds HR, Rosenberg Y et al.; ISCHEMIA Research Group. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 2020;382:1408–19.

25. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pillai IL et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction. Circulation 2020;142:1725–35.

26. van de Hoef TP, Nolte F, Echavarria-Pinto M, van Lavieren MA, Damman P, Chamuleau SA et al. Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: Insights from combined stenosis and microvascular resistance assessment. Heart 2014;100:951–9.

27. Bui L, Kikugawa D, Roby AE, Nguyen TT, Gould KL. Pitfalls in quantitative myocardial PET perfusion II: arterial input function. J Nucl Cardiol 2020;27:397–409.